CytoSorbents

CTSO48

Penny Stock

$1.130.00%$0.00

Penny Stock

CTSO48

$1.13

0.00%$0.00

Penny Stock

Performance History

Key Stats
Open	$1.10
Prev. Close	$1.12
EPS	-0.52
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$59.87M
PE Ratio	-

	LOW	HIGH
Day Range	1.07	1.13
52 Week Range	0.70	2.15

Ratios







EPS	-0.52

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About CytoSorbents (CTSO)

CytoSorbents Corp, also known as CTSO, is a medical technology company specializing in blood purification. The company is focused on developing and commercializing its flagship product, CytoSorb, which is designed to remove a broad range of harmful substances from the bloodstream. CytoSorb is used in critical care settings to treat conditions such as sepsis and multiple organ dysfunction syndrome. The device works by adsorbing toxins and cytokines, which can contribute to organ failure and death. By removing these harmful substances, CytoSorb helps to improve patient outcomes and reduce the burden on the healthcare system.

CTSO has experienced significant growth in recent years, driven by increasing demand for its products and strong clinical evidence supporting the effectiveness of CytoSorb. The company has expanded its global footprint and established partnerships with leading healthcare providers to maximize market penetration. With a market cap of over $500 million, CTSO is well-positioned for future success.

Websitecall_made

Sector: Healthcare
Industry: Medical Devices
CEO: Dr. Phillip P. Chan M.D., Ph.D.
Headquarters: Princeton
Employees: 198
Exchange: NASDAQ

Keep an eye on CytoSorbents

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is CytoSorbents's (CTSO) price per share?

The current price per share for CytoSorbents (CTSO) is $1.13. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for CytoSorbents (CTSO)?

For CytoSorbents (CTSO), the 52-week high is $2.15, which is 90.27% from the current price. The 52-week low is $0.7, the current price is 61.43% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is CytoSorbents (CTSO) a growth stock?

CytoSorbents (CTSO) has shown an average price growth of -1.93% over the past three years. It has received a score of 13 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying CytoSorbents as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is CytoSorbents (CTSO) stock price performance year to date (YTD)?

As of the latest data, CytoSorbents (CTSO) has a year-to-date price change of 5.61%. Over the past month, the stock has experienced a price change of -8.87%. Over the last three months, the change has been 0.89%. Over the past six months, the figure is 41.66%. Looking at a longer horizon, the five-year price change stands at -75.38%.

help

Is CytoSorbents (CTSO) a profitable company?

CytoSorbents (CTSO) has a net income of -$28.51M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 61.6% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -32.68% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $36.35M, with a revenue growth rate of 23.81%, providing insight into the company's sales performance and growth. The gross profit is $22.39M. Operating income is noted at -$30.55M. Furthermore, the EBITDA is -$22.61M.

help

What is the market capitalization of CytoSorbents (CTSO)?

CytoSorbents (CTSO) has a market capitalization of $59.87M. The average daily trading volume is 1.11, indicating the stock's liquidity and investor engagement.